EMAIL THIS PAGE TO A FRIEND

Cancer immunology research

Untreated stage IV melanoma patients exhibit abnormal monocyte phenotypes and decreased functional capacity.


PMID 24778320

Abstract

Monocytes may contribute to tumor progression in part by mediating tumor-induced immunosuppression. Alterations to the monocyte populations and functions in untreated patients with late-stage melanoma are not fully understood. To characterize these alterations, we compared the frequency, phenotype, and functional capacity of peripheral blood monocytes and other myeloid cells in untreated, newly diagnosed stage IV melanoma patients (n = 18) with those in healthy volunteers. Stage IV untreated melanoma patients exhibited a sizeable decrease in the percentage of monocytes (P < 0.0001) that included a drop in the percentage of the CD14(+)CD16(-) classical monocyte pool (P = 0.006). Although there was not a significant difference in the CD14(+)HLA-DR(low/-) monocyte population between the patients with melanoma and the healthy volunteers, the HLA-DR levels were considerably lower in the patients' CD14(+)CD16(+) intermediate (P < 0.0001) and CD14(low)CD16(+) nonclassical monocyte populations (P = 0.001). Decreased surface expression of CD86 (P = 0.0006) and TNFRII (P = 0.0001) and increased expression of tissue factor and PD-L1 (P = 0.003) were identified on monocytes from patients with melanoma. Furthermore, these monocytes had decreased ability to upregulate CD80 expression and cytokine production following stimulation with agonist of Toll-like receptor 3 (TLR3). Peripheral blood dendritic cell subsets were decreased in untreated stage IV melanoma patients. Our study demonstrates that untreated late-stage melanoma patients exhibit monocytopenia in addition to phenotypic and functional deficiencies that may negatively affect their immune function. These findings open new avenues into examining the role of monocyte populations in melanoma development.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB2502013
Anti-CD7 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB1405576
Anti-CD7 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB1401056
Anti-CD7 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB1406022
Anti-IL3RA antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
HPA003539
Anti-IL3RA antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB2700234
Anti-Ncam1 (N-terminal) antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2501672
Anti-NCAM1 antibody produced in goat, affinity isolated antibody, buffered aqueous solution
SAB4300660
Anti-NCAM1 antibody produced in rabbit, affinity isolated antibody
SAB2501275
Anti-THY1 antibody produced in goat, affinity isolated antibody
HPA003733
Anti-THY1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
WH0000930M1
Monoclonal Anti-CD19 antibody produced in mouse, clone 1G3, purified immunoglobulin, buffered aqueous solution
SAB1403645
Monoclonal Anti-CD19 antibody produced in mouse, clone 1C9, purified immunoglobulin, buffered aqueous solution
SAB4700108 Monoclonal Anti-CD19 antibody produced in mouse, clone 4G7, purified immunoglobulin, buffered aqueous solution
SAB4700109 Monoclonal Anti-CD19 antibody produced in mouse, clone LT19, purified immunoglobulin, buffered aqueous solution
SAB4700449 Monoclonal Anti-CD56 antibody produced in mouse, clone MEM-188, purified immunoglobulin, buffered aqueous solution
WH0000924M4
Monoclonal Anti-CD7 antibody produced in mouse, clone 1B8, purified immunoglobulin, buffered aqueous solution
SAB4700079 Monoclonal Anti-CD7 antibody produced in mouse, clone MEM-186, purified immunoglobulin, buffered aqueous solution
WH0004684M1
Monoclonal Anti-NCAM1 antibody produced in mouse, clone 3G12, purified immunoglobulin, buffered aqueous solution
WH0007070M1
Monoclonal Anti-THY1 antibody produced in mouse, clone 3F9, purified immunoglobulin, buffered aqueous solution
SAB4200497
Monoclonal Anti-THY1 antibody produced in mouse, ~1.0 mg/mL, purified immunoglobulin
AMAB90846
Monoclonal Anti-THY1 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1040, purified immunoglobulin, buffered aqueous glycerol solution
AMAB90844
Monoclonal Anti-THY1 antibody produced in mouse, Prestige Antibodies® Powered by Atlas Antibodies, clone CL1028, purified immunoglobulin, buffered aqueous glycerol solution